What are the primary reasons for patients lapsing (cured, time, cost), what is the mix, and how does the company target them for return?

The three main drivers for lapsing are pain, time, and money. Consumer research shows lapsed patients have positive memories and are willing to reconsider. The company is actively targeting them with digital and local marketing efforts, including an August promotion. Flexible plan options like Align One ($35/month for one visit) have significantly improved conversion rates for lapsed patients. “What we found is we've done consumer research, is that unlike several brands where the lapsed patients tend to have some degree of disgruntlement with the concept, our lapsed patients actually have fond memories of getting pain relief and are very willing to reconsider us.”

Provide more detail on comp trends throughout Q2 and July, and quantify the benefit of pricing in Q2 and expectations for H2.

Comp sales improved towards the end of Q2 and into Q3, with July comps being 'a bit better' than Q2's close. Pricing initiatives contributed in the low single-digit range in Q2, and with more clinics adopting new pricing, H2 is expected to see the high end of that low single-digit impact. Pricing is applied only to new patients, so the full impact takes time. “As far as comps go, We did see a little bit better comps towards the end of the quarter. and coming into third quarter.”

Clarify the 'starting point' nature of the pro forma profitability targets (19-21% adjusted EBITDA margin) and where future opportunities for margin expansion lie (growth/scale vs. direct cost reduction).

The pro forma model is a 'starting point' post-re-franchising, not a long-term projection. The current structure allows for leveraging additional sales to expand profitability. Specific non-recurring expenses (approx. $500,000 in Q2 related to RD buybacks and re-franchising costs) currently in SG&A will not recur, helping achieve G&A targets. Further optimization areas will become clearer post-re-franchising completion. “The model that is in the earnings deck, I wanted to make sure that everybody understood that this is a starting point for us. ... Now it's kind of point in time, what we would expect.”

JYNT

JOINT (JYNT) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

The Joint Corp. Q2 FY26 — Re-franchising Nears Completion, Driving Profitability and Patient Retention

The Joint Corp. continued its "Joint 2.0" initiative in Q2 FY26, nearing completion of its re-franchising efforts to transition to a capital-light franchisor model. This strategic shift is driving improved profitability and free cash flow, with significant year-over-year increases in net income and adjusted EBITDA. The company also achieved its best patient retention rate in over five years, attributed to new flexible plan options and targeted marketing, despite a decline in system-wide sales and negative comparable sales.

Highlights

Consolidated net income improved by $560,000 year-over-year to $653,000.
Adjusted EBITDA from continuing operations increased by $1.4 million year-over-year to $1.5 million.
Cash flow from operating activities grew 152% year-over-year to $2.2 million.
Free cash flow increased by $1.6 million year-over-year to $1.9 million.
Patient retention rate was the best in over five years, driven by new flexible plan options.

Concerns

System-wide sales declined 3.7% year-over-year to $128 million.
Comp sales were negative 2.8% in Q2 FY26.
New clinic openings guidance for FY26 lowered to 22-26 from 30-35.
Net clinic count at year-end 2026 is expected to be lower than 2025 due to portfolio optimization and closures.

Guidance & targets

Category	Target	Timeline	Confidence
FY26 System-wide sales	$519 million to $552 million high materiality	FY26	High
FY26 Comp sales	negative 3% to positive 3% high materiality	FY26	High
FY26 Consolidated adjusted EBITDA	$12.5 million to $13.5 million high materiality	FY26	High
FY26 New franchise clinic openings	22 to 26 medium materiality	FY26	High
Comp sales trend	improve throughout the balance of this year high materiality	H2 FY26	High
Gross margin (pure play franchisor model)	between 83% and 85% of revenues high materiality	starting in H2 FY26	High
G&A expense (pure play franchisor model)	between 40% and 42% of revenues high materiality	starting in H2 FY26	High
CapEx (pure play franchisor model)	approximately 3% of revenues medium materiality	starting in H2 FY26	High
Free cash flow conversion (pure play franchisor model)	between 60% and 70% high materiality	starting in H2 FY26	High
Adjusted EBITDA margin (pure play franchisor model)	19% to 21% high materiality	starting in H2 FY26	High
Net income margin (pure play franchisor model)	13% to 15% high materiality	starting in H2 FY26	High
Long-term franchise clinics in U.S.	more than 1,800 high materiality	long-term	High

Deals & partnerships

Unnamed buyer Sale of clinics, transitioning to management service agreements pending lease assignments.

Ownership has been transferred for 32 clinics to date and the remaining 13 clinics are being operated by the buyer under management service agreements while lease assignments are finalized for the Southern California bundle.

Unnamed buyer Sale of clinics.

A signed asset purchase agreement is in place for four clinics for the Northern California bundle.

Unnamed buyer Sale of clinics, transitioning to management service agreements pending lease assignments.

Ownership has been transferred for six clinics to date, with the remaining 15 clinics also operating under management service agreements pending lease reassignments for the Southeast bundle.

Regional Developers Acquisition of regional developer territories to optimize portfolio economics.

Completed three regional developer territory buybacks in the quarter, bringing the year-to-date total to four.

Risks & headwinds

System-wide sales decline Q2 FY26

3.7% year-over-year decline to $128 million

Mitigation:Focus on driving growth through franchise system support, new patient acquisition, and long-term network development.

Negative comparable sales Q2 FY26

Negative 2.8% in Q2 FY26

Mitigation:Flexible membership options, pricing optimization, improving active member trends, lead generation, and winning back lapsed patients. Expected to improve throughout H2 FY26.

Lower net clinic count FY26

Net clinic count at the end of 2026 will be lower than 2025

Mitigation:Strategic portfolio optimization to reshape around stronger operators and healthier sites, building a more durable foundation for future growth.

Lower new clinic openings guidance FY26

FY26 guidance lowered to 22-26 from 30-35

Mitigation:Focus on quality over quantity, bringing on well-capitalized franchisees with multi-site operating experience.

What to watch in Q3 FY26

Comp sales trend

Q3 FY26, Q4 FY26

Current Negative 2.8% in Q2 FY26, 'a bit better' in July

Target Improvement throughout H2 FY26, with Q4 higher than Q3

Why it matters

Indicates the effectiveness of patient retention, pricing, and marketing strategies, crucial for revenue growth.

We expect comp sales to improve in the second half of the year, with the fourth quarter expected to be higher than the third quarter.

Find out whether JYNT delivers this. Inve re-checks your case every morning.

Q&A highlights

How is the company operating in the new AI search environment to ensure customer click-through to its website, given changes like Google's click rates going to zero?

Management stated they stay ahead through three ways: feedback from 260 local franchisees, a dedicated digital marketing team monitoring algorithm changes across platforms, and objective measurement systems. Their AI search score has improved from the low 70s to the high 70s.

“For when we started this journey sometime I would say late last year, our AI score, search score was in the low 70s, 71 to be precise. And for the last several months now, we have been in the high 70s.”

asked by Nicholas Sherwood · answered by Unknown Speaker

2 min read 6 chapters

Detailed narrative

Re-franchising Progress and Capital-Light Model

The company is nearing completion of its re-franchising initiative, with ownership transferred for 32 clinics in Southern California and 6 clinics in the Southeast bundle. Remaining clinics are operating under management service agreements pending lease assignments. This transition positions the company as a capital-light, pure-play franchisor, expected to realize full benefits in H2 2026, leading to higher profitability and stronger free cash flow.

Only three company-owned or managed clinics will remain once transfers are finalized.

Patient Retention and Flexible Plan Options

Patient retention rates reached a five-year high in Q2 FY26, directly attributed to the introduction of new flexible and expanded plan options earlier this year. These options, such as the Align One plan ($35 for one visit/month, additional visits for $25), have significantly improved conversion rates for lapsed patients and are reducing attrition.

The company is actively targeting lapsed patients with marketing efforts, including an August promotion.

Digital Marketing and AI Optimization

The Joint Corp. is actively optimizing its digital marketing strategy, including SEO and AI visibility. The company's AI visibility score has consistently held in the high 70s, outperforming competitors. This focus drives higher organic traffic and lead quality to local clinic microsites, supported by continuous monitoring of algorithm changes and local franchisee feedback. This strategy aims to effectively capture demand and improve patient acquisition.

Pricing Strategy and Impact

The company expanded its $5 and $10 pricing increases to over 500 clinics in July. Feedback indicates no meaningful patient pushback, and the strategy is designed to optimize revenue without negatively impacting patient acquisition or retention. Pricing changes are primarily applied to new patients, with the full impact expected to materialize over time as more patients transition to the current pricing model, contributing to low single-digit revenue growth.

Clinic Portfolio Optimization

The company opened 5 clinics, closed 7, and re-franchised 29 clinics in Q2 FY26, reflecting a strategy to optimize the portfolio for quality and performance. New clinics opened in 2026 are outperforming prior cohorts and reaching break-even in under six months.

The overall net clinic count is expected to be lower by year-end 2026, but this is seen as building a stronger, more durable foundation for future growth, with potential for over 1,800 franchise clinics in the U.S. alone.

Capital Allocation and RD Buybacks

The company repurchased approximately 82,000 shares for $677,000 at an average price of $8.23 per share, with $3.8 million remaining under the $12 million authorization. Additionally, three regional developer (RD) territory buybacks were completed in Q2 (four year-to-date), which are expected to reduce RD royalties by approximately $630,000 on an annualized basis, partially offset by internal management costs.

These actions reflect conviction in long-term value and commitment to stockholder returns.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.